Direkt zum Inhalt
Merck

SML0937

Darunavir

≥98% (HPLC), HIV protease inhibitor, powder

Synonym(e):

TMC-114, UIC-94017, [(1R,5S,6R)-2,8-dioxabicyclo[3.3.0]oct-6-yl] N-[(2S,3R)-4- [(4-aminophenyl)sulfonyl- (2-methylpropyl)amino]-3-hydroxy-1-phenyl- butan-2-yl]

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

10 MG

€ 124,00

50 MG

€ 488,00

€ 124,00


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C27H37N3O7S
CAS-Nummer:
Molekulargewicht:
547.66
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

Darunavir, ≥98% (HPLC)

SMILES string

[H][C@]1([C@@H](OC(N[C@@H](CC2=CC=CC=C2)[C@@H](CN(S(C3=CC=C(N)C=C3)(=O)=O)CC(C)C)O)=O)CO4)[C@]4([H])OCC1

InChI

1S/C27H37N3O7S/c1-18(2)15-30(38(33,34)21-10-8-20(28)9-11-21)16-24(31)23(14-19-6-4-3-5-7-19)29-27(32)37-25-17-36-26-22(25)12-13-35-26/h3-11,18,22-26,31H,12-17,28H2,1-2H3,(H,29,32)/t22-,23-,24+,25-,26+/m0/s1

InChI key

CJBJHOAVZSMMDJ-HEXNFIEUSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 20 mg/mL, clear

shipped in

wet ice

storage temp.

−20°C

Quality Level

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
SML0685SML1883SML2357
form

powder

form

powder

form

powder

form

powder

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

100

Quality Level

100

Quality Level

100

Quality Level

-

storage temp.

−20°C

storage temp.

−20°C

storage temp.

−20°C

storage temp.

2-8°C

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 20 mg/mL, clear

solubility

DMSO: 2 mg/mL, clear

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

-

Biochem/physiol Actions

Darunavir has been sanctioned by the food and drug administration (FDA) as the first treatment of drug-resistant human immunodeficiency virus (HIV).[1]
Darunavir is a HIV protease inhibitor; antiretroviral.
Darunavir is a second-generation antiviral HIV protease inhibitor with broad spectrum activity.

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Michael S Saag et al.
JAMA, 320(4), 379-396 (2018-07-26)
Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. To evaluate new data and treatments and incorporate this information into updated recommendations for initiating therapy, monitoring individuals starting therapy, changing regimens, and preventing HIV infection for
Beatriz Grinsztejn et al.
The lancet. HIV, 6(9), e588-e600 (2019-08-03)
Antiretroviral therapy (ART) management is challenging for individuals in resource-limited settings presenting for third-line treatment because of complex resistance patterns, partly due to reduced access to viral load monitoring. We aimed to evaluate use of newer antiretroviral drugs and contemporary
Joseph J Eron et al.
AIDS (London, England), 32(11), 1431-1442 (2018-04-24)
To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infected adults. Phase-3, randomized, active-controlled, double-blind, international, multicenter, noninferiority study (NCT02431247). Seven hundred and twenty-five participants
Thomas N Kakuda et al.
Antiviral therapy, 19(6), 597-606 (2014-06-26)
Darunavir requires pharmacokinetic enhancement to increase its bioavailability. Cobicistat is potentially an alternative pharmacokinetic booster to ritonavir. Bioequivalence of a darunavir/cobicistat fixed-dose combination (FDC) versus darunavir and cobicistat co-administered as single agents and the effect of a high-fat meal on
David Wu et al.
Journal of clinical medicine, 9(6) (2020-06-21)
The current COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. The virus causes severe respiratory symptoms which manifest disproportionately in the elderly. Currently, there are over 6.5 million cases and 380,000 deaths reported. Given the current severity of the

Artikel

Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung